Can dasatinib inhibit leukemia bone marrow cells?

Dasatinib inhibits leukemia bone marrow cells. Dasatinib is an anti-tumor drug with a unique protein kinase inhibition mechanism. It exerts strong inhibitory effects on leukemia cell lines expressing imatinib-sensitive and -resistant disease by precisely inhibiting oncogenic kinases. This inhibitory effect can effectively control the growth of cancer cells.

For patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML), dasatinib has shown excellent therapeutic effects whether in the chronic phase, accelerated phase or blast phase. It also provides new treatment opportunities for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to other therapies.

Dasatinib can interfere with thePDGFRα/β signaling pathway and alleviate symptoms caused by overactivation of this receptor, suggesting that leukemic myeloid cells are also affected.

In addition to inhibitingBCR-ABLkinase, dasatinib can also inhibitPDGFRα/β, c-KIT, TIE-2 and FLT-3 and other kinases, these kinases play a key role in the proliferation and differentiation of leukemia bone marrow cells. Therefore, by inhibiting these kinases, dasatinib is able to effectively control the growth and spread of leukemia bone marrow cells.

Studies have shown that dasatinib has shown efficacy and safety in Chinese children with core-binding factor acute myeloid leukemia. This shows that dasatinib has actual clinical effect in inhibiting leukemia bone marrow cells.

Although dasatinib is excellent at inhibiting leukemia bone marrow cells, it is necessary to be alert to possible side effects, such as bone marrow suppression, allergic reactions, etc. when using it. Therefore, careful guidance and close monitoring by a physician is required when using this medication.